Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    Verrica Pharmaceuticals Inc. (VRCA)

    3.5900 +0.4000 (+12.54%)
    At close: November 9 at 4:00:00 PM EST
    VRCA Q3 2026 earnings call
    November 12, 2026 at 4:30 PM EST
    Loading Chart for VRCA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026

    Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
    GlobeNewswire 4d ago
    Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

    Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
    GlobeNewswire 19d ago
    Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

    Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
    GlobeNewswire 1mo ago
    Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

    Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
    GlobeNewswire 1mo ago
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
    GlobeNewswire 2mo ago
    Verrica completes enrolment in Phase III trial of Ycanth

    Verrica completes enrolment in Phase III trial of Ycanth
    Hospital Management 2mo ago
    Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

    Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
    GlobeNewswire 2mo ago
    Verrica Pharmaceuticals Q2 Earnings Call Highlights

    Verrica Pharmaceuticals Q2 Earnings Call Highlights
    MarketBeat 3mo ago
    Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

    Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
    Zacks 3mo ago
    Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

    Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
    GlobeNewswire 3mo ago
    Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

    Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
    GlobeNewswire 4mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: